Filter posts

On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer This week, BIO launched a …

On the President’s Drug Cost Plan, Three Important Concerns

Part 2. Upending Access in Medicare Part B program This week, BIO launched a three-part …

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its …

Value Assessment Tools that take “Precision” out of “Precision Medicine” are Harmful to Pati...

The conversation about health care costs is front and center in Washington, and new data …

A New Approach to Assessing Value in Health Care

It’s an important and exciting time in the biotech industry. Spending on prescription drugs has …

Harvard Analysis of Discriminatory Formulary Design in 2016 Health Plans

BIO supports policy changes that protect patients’ ability to obtain access to the prescription drugs …